Table 1.
Patient demographics and outcomes
| Patient study number |
Sex (M/F) |
Ethnicity | Age | Type of Cancer |
Prior Treatments |
Active Disease Sites |
Stage | Number of NY-ESO-1 TCR transgenic cells |
IL-2 doses |
DC doses |
Evidence of transient tumor response |
Response at EOS (day 90) |
PFS (mo) |
OS (mo) |
Sites of Progression |
Post-Study Treatments |
Current Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESO-1 | M | Hispanic | 47 | Liposarcoma | Surgery; Radiation; Gemcitabine +docetaxel +ontuxizumab; doxorubicin +ifosfamide |
Right Renal Fossa; Liver left Lobe; Hepatic Segment; Peritoneal, Perihepatic Nodule |
IV | 7.7 × 108 | 28/28 | 3/3 | No | PD | 2.6 | 16 | Liver | Trabectedin, pazopanib | Died of disease |
| ESO-2 | M | Hispanic | 37 | Malignant Peripheral Nerve Sheath Tumor | Surgery; Radiation; Gemcitabine +docetaxel; doxorubicin +ifosfamide; trabectedin; navelbine +avastin +cytoxan; pexidartinib |
Right Iliopsoas; Peritoneal; Retroperitoneal |
IV | 1 × 109 | 28/28 | 3/3 | No | NA | NA | 1.3 | NA | NA | Died of disease |
| ESO-3 | F | Caucasian | 24 | Synovial Sarcoma | Surgery; Radiation; doxorubicin +ifosfamide +gemcitabine +doxetaxel |
Right Lung; Multiple pulmonary Nodules |
IV | 1 × 109 | 19/28 | 1/3 | Yes by PET/CT | PR | 51 | 51 | NA | NA | Alive with CR |
| ESO-4 | M | Caucasian | 41 | Synovial Sarcoma | Surgery; Radiation; Doxorubicin +ifosfamide; Gemcitabine +docetaxel; pazopanib |
Left Infraclavicular Mass; Left Pectoralis Mass |
III | 1 × 109 | 18/28 | 3/3 | Yes by PET/CT | PD | 3 | 25 | Left pectoralis mass | Ifosfamide, nivolumab, Yondelis | Died of disease |
| ESO-5 | F | Caucasian | 43 | Synovial Sarcoma | Surgery; doxorubicin +ifosfamide; radiation |
Right popliteal fossa; Lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PR | 9 | 43 | Intrathoracic LN and pulmonary nodules | INY | Alive with disease |
| ESO-6 | M | Caucasian | 26 | Osteosarcoma | Surgery; doxorubicin +cisplatin +methotrexate +ifosfamide +etoposide; gemcitabine +docetaxel; MAGE-A3 transgenic TCR ACT; Nivolumab +ipilimumab |
Lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 2.5 | 19 | Right Upper Lobe Lung, Left Lower Lobe Lung | NA | Died of disease |
| INY-1 | M | Caucasian | 51 | Synovial Sarcoma | Surgery, doxorubicin +ifosfamide; Pazopanib |
Lung, bone marrow | IV | 1 × 109 | 18/28 | 3/3 | No | NA | NA | 2 | NA | NA | Died of disease |
| INY-2 | M | Caucasian | 66 | Melanoma | Vemurafenib, Ipilimumab | LN, Liver | IV | 1 × 109 | 21/28 | 2/3 | Yes by PET/CT | PD | 3 | 6 | Thigh, Abdominal mesentery, parenchymal nodules, mediastinal nodes, brain, right orbit, chest wall | NA | Died of disease |
| INY-3 | F | Caucasian | 44 | Synovial Sarcoma | Surgery; doxorubicin +ifosfamide; radiation |
Right popliteal fossa; Lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 3 | 29 | Right popliteal fossa, soft tissue posterior to the right femur, intrathoracic LN and pulmonary nodules | Nivolumab, pazopanib | Alive with disease |
| INY-4 | M | Hispanic | 24 | Melanoma | Nivolumab +ipilimumab; dabrafenib +trametinib +nivolumab |
Lung, LN, adrenal gland, liver, trachea, brain | IV | 1 × 109 | 10/14 | 3/3 | No | PD | NA | 3 | Lung, adrenal gland, bone marrow | Nivolumab, anti-CD137 | Died of disease |
Abbreviations: F: female; LN: lymph nodes; M: male; NA: not available; PFS: progression-free survival; OS: overall survival; EOS: end of study; DC: dendritic cells; TCR: T cell receptor; IL-2: interleukin-2; mo: months